Cancer Research UK and Sosei Heptares Sign Agreement to Advance Cancer Immunotherapy Candidate into Clinical Trials

Sosei Group Corporation and Cancer Research UK announced the signing of an agreement to bring Sosei Heptares’ cancer immunotherapy drug candidate into a first-in-human trial.